m-Eslon SR

País: Nueva Zelanda

Idioma: inglés

Fuente: Medsafe (Medicines Safety Authority)

Ingredientes activos:

Morphine sulfate pentahydrate 100mg;  

Disponible desde:

Multichem NZ Limited

Designación común internacional (DCI):

Morphine sulfate pentahydrate 100 mg

Dosis:

100 mg

formulario farmacéutico:

Modified release capsule

Composición:

Active: Morphine sulfate pentahydrate 100mg   Excipient: Dibutyl sebacate Ethylcellulose Gelatin   Macrogol 4000 Purified talc Sugar spheres Titanium dioxide

Unidades en paquete:

Blister pack, Al/PVC, 10 capsules

clase:

Class B1 Controlled Drug

tipo de receta:

Class B1 Controlled Drug

Fabricado por:

Siegfried Ltd

indicaciones terapéuticas:

For the prolonged relief of chronic, moderate to severe pain in adults. Use in Non-Malignant Pain: The use of m-Eslon SR tablets for the treatment of pain which is not due to malignancy should be restricted to situations where: o All other conservative methods of analgesia have been tried and have failed; o The pain is having a significant impact on the patient's quality of life; o There is no psychological contraindication, drug seeking behaviour or history of drug misuse.

Resumen del producto:

Package - Contents - Shelf Life: Blister pack, Al/PVC - 10 capsules - 36 months from date of manufacture stored at or below 25°C

Fecha de autorización:

2001-03-13

Ficha técnica

NEW ZEALAND DATA SHEET
M-ESLON
Page 1 of 17
1. PRODUCT NAME
m-Eslon SR, morphine sulphate, modified release capsule, 10 mg, 30 mg,
60 mg, 100 mg and
200 mg.
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
m-Eslon SR 10 mg: each capsule contains microgranules providing 10 mg
of morphine sulphate.
m-Eslon SR 30 mg: each capsule contains microgranules providing 30 mg
of morphine sulphate.
m-Eslon SR 60 mg: each capsule contains microgranules providing 60 mg
of morphine sulphate.
m-Eslon SR 100 mg: each capsule contains microgranules providing 100
mg of morphine
sulphate.
m-Eslon SR 200 mg: each capsule contains microgranules providing 200
mg of morphine
sulphate.
For the full list of excipients see 6.1.
3. PHARMACEUTICAL FORM
Modified release capsules filled with off-white spherical
microgranules.
m-Eslon SR 10 mg: size 4 capsules with natural transparent body and
yellow cap, printed 10
mg in black ink.
m-Eslon SR 30 mg: size 4 capsules with natural transparent body and
pink cap, printed 30 mg
in black ink.
m-Eslon SR 60 mg: size 3 capsules with natural transparent body and
orange cap, printed 60
mg in black ink.
m-Eslon SR 100 mg: size 2 capsules with natural transparent body and
white cap, printed 100
mg in black ink.
m-Eslon SR 200 mg: size 0 capsules with natural transparent body and
cap, printed 200 mg in
black ink.
4. CLINICAL PARTICULARS
4.1
Therapeutic indications
For the prolonged relief of chronic, moderate to severe pain in
adults.
Use in Non-Malignant Pain
The use of m-Eslon SR for the treatment of pain which is not due to
malignancy should be
restricted to situations where:
-
All other conservative methods of analgesia have been tried and have
failed;
NEW ZEALAND DATA SHEET
M-ESLON
Page 2 of 17
-
The pain is having a significant impact on the patient’s quality o
f life;
-
There is no psychological contraindication, drug seeking behaviour or
history of drug
misuse.
4.2
Dose and method of administration
Administration and dosing of morphine should be individualised bearing
in mind the properties
of the drug